Registration Dossier
Registration Dossier
Data platform availability banner - registered substances factsheets
Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.
The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.
Diss Factsheets
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 485-320-2 | CAS number: 221667-31-8
- Life Cycle description
- Uses advised against
- Endpoint summary
- Appearance / physical state / colour
- Melting point / freezing point
- Boiling point
- Density
- Particle size distribution (Granulometry)
- Vapour pressure
- Partition coefficient
- Water solubility
- Solubility in organic solvents / fat solubility
- Surface tension
- Flash point
- Auto flammability
- Flammability
- Explosiveness
- Oxidising properties
- Oxidation reduction potential
- Stability in organic solvents and identity of relevant degradation products
- Storage stability and reactivity towards container material
- Stability: thermal, sunlight, metals
- pH
- Dissociation constant
- Viscosity
- Additional physico-chemical information
- Additional physico-chemical properties of nanomaterials
- Nanomaterial agglomeration / aggregation
- Nanomaterial crystalline phase
- Nanomaterial crystallite and grain size
- Nanomaterial aspect ratio / shape
- Nanomaterial specific surface area
- Nanomaterial Zeta potential
- Nanomaterial surface chemistry
- Nanomaterial dustiness
- Nanomaterial porosity
- Nanomaterial pour density
- Nanomaterial photocatalytic activity
- Nanomaterial radical formation potential
- Nanomaterial catalytic activity
- Endpoint summary
- Stability
- Biodegradation
- Bioaccumulation
- Transport and distribution
- Environmental data
- Additional information on environmental fate and behaviour
- Ecotoxicological Summary
- Aquatic toxicity
- Endpoint summary
- Short-term toxicity to fish
- Long-term toxicity to fish
- Short-term toxicity to aquatic invertebrates
- Long-term toxicity to aquatic invertebrates
- Toxicity to aquatic algae and cyanobacteria
- Toxicity to aquatic plants other than algae
- Toxicity to microorganisms
- Endocrine disrupter testing in aquatic vertebrates – in vivo
- Toxicity to other aquatic organisms
- Sediment toxicity
- Terrestrial toxicity
- Biological effects monitoring
- Biotransformation and kinetics
- Additional ecotoxological information
- Toxicological Summary
- Toxicokinetics, metabolism and distribution
- Acute Toxicity
- Irritation / corrosion
- Sensitisation
- Repeated dose toxicity
- Genetic toxicity
- Carcinogenicity
- Toxicity to reproduction
- Specific investigations
- Exposure related observations in humans
- Toxic effects on livestock and pets
- Additional toxicological data
![](https://echa.europa.eu/o/diss-blank-theme/images/factsheets/A-REACH/factsheet/print_toxicological-information.png)
Toxicological Summary
- Administrative data
- Workers - Hazard via inhalation route
- Workers - Hazard via dermal route
- Workers - Hazard for the eyes
- Additional information - workers
- General Population - Hazard via inhalation route
- General Population - Hazard via dermal route
- General Population - Hazard via oral route
- General Population - Hazard for the eyes
- Additional information - General Population
Administrative data
Workers - Hazard via inhalation route
Systemic effects
Long term exposure
- Hazard assessment conclusion:
- DNEL (Derived No Effect Level)
- Value:
- 13.8 mg/m³
- Most sensitive endpoint:
- repeated dose toxicity
- Route of original study:
- Oral
DNEL related information
- DNEL derivation method:
- ECHA REACH Guidance
- Overall assessment factor (AF):
- 5
- Dose descriptor starting point:
- NOAEL
- Value:
- 39 mg/kg bw/day
- Modified dose descriptor starting point:
- NOAEC
- Value:
- 68.8 mg/m³
- Explanation for the modification of the dose descriptor starting point:
The calculation of the DNEL is based on an oral NOAEL observed in an oral combined repeated dose toxicity / carcinogenicity study (OECD 453; 2006).
To correct the interspecies difference between rat and human the NOAEL has to be corrected as follows:
Corrected starting point for the inhalative route for workers:
= NOAEL(oral) * (1/0.38 m³/kg bw/day) * (ABSoral-rat/ABSinh-human) * (6.7 m³ (8h) /10 m³ (8h))
As described in the ECHA Guidance R.8 (2012), it is assumed that inhalation absorption is 100%. In the toxicokinetic studies with the test substance it was shown that the oral absorption is close to 100%. (ABSoral-rat = oral absorption in rats, ABSinh-human = inhalation absorption rate in humans).
= 39 mg/kg bw/day * (1/0.38 m³/kg bw/day) * (1/1) * 0.67 m³ = 68.8 mg/m³
Thus, the corrected starting point for workers was 68.8 mg/m³ for inhalation.
- AF for dose response relationship:
- 1
- Justification:
- The dose descriptor starting point is based on a NOAEL
- AF for differences in duration of exposure:
- 1
- Justification:
- The DNEL is based on a chronic study
- AF for interspecies differences (allometric scaling):
- 1
- Justification:
- Allometric scaling not used for inhalation route
- AF for other interspecies differences:
- 1
- Justification:
- The toxicokinetic data indicate that the test substance will not be metabolised
- AF for intraspecies differences:
- 5
- Justification:
- Default value for workers according to ECHA REACH Guidance
- AF for the quality of the whole database:
- 1
- Justification:
- The DNEL is based on a high-quallity study
- AF for remaining uncertainties:
- 1
- Justification:
- No remaining uncertainties
Acute/short term exposure
- Hazard assessment conclusion:
- no hazard identified
- Most sensitive endpoint:
- acute toxicity
- Route of original study:
- By inhalation
DNEL related information
Local effects
Long term exposure
- Hazard assessment conclusion:
- no hazard identified
Acute/short term exposure
- Hazard assessment conclusion:
- no hazard identified
- Most sensitive endpoint:
- acute toxicity
DNEL related information
Workers - Hazard via dermal route
Systemic effects
Long term exposure
- Hazard assessment conclusion:
- DNEL (Derived No Effect Level)
- Value:
- 52 mg/kg bw/day
- Most sensitive endpoint:
- repeated dose toxicity
- Route of original study:
- Oral
DNEL related information
- DNEL derivation method:
- ECHA REACH Guidance
- Overall assessment factor (AF):
- 50
- Dose descriptor starting point:
- NOAEL
- Value:
- 39 mg/kg bw/day
- Modified dose descriptor starting point:
- NOAEL
- Value:
- 2 600 mg/kg bw/day
- Explanation for the modification of the dose descriptor starting point:
The calculation of the dermal DNEL is based on the oral NOAEL of 39 mg/kg bw/day observed in an oral combined repeated dose toxicity / carcinogenicity study (OECD 453, 2006). The NOAEL is corrected to account for dermal penetration rates through human skin. For the test substance, an in vitro dermal penetration study using human skin is available (M-279026-01-2, 2006). The study was performed by the use of the test substance in an agrochemical formulation (SC450) at two concentrations: the neat product (nominal value = 225 mg/mL) and a representative spray dilution (nominal value = 0.27 mg/mL) were tested. For the neat product, the mean percentage of the test substance considered to be potentially absorbable over a period of 24 h was 0.85%. For the spray dilution, the mean percentage of the test substance potentially absorbable over a period of 24 h was 1.5%. As the workers will only be exposed to the formulation and not to the active substance, the % absorbed through the human skin assessed by the in vitro dermal penetration study is taken into account in the DNEL derivation. The oral absorption rate is assumed to be 100%, based on almost complete oral absorption seen in the toxicokinetic studies.
Corrected dermal NOAEL = 39 * (100/1.5) = 2600 mg/kg bw/day
- AF for dose response relationship:
- 1
- Justification:
- The dose descriptor starting poiont is based on a NOAEL
- AF for differences in duration of exposure:
- 1
- Justification:
- The DNEL is based on a chronic study
- AF for interspecies differences (allometric scaling):
- 4
- Justification:
- The experimental animal was rat
- AF for other interspecies differences:
- 2.5
- Justification:
- Default value according to ECHA REACH Guidance
- AF for intraspecies differences:
- 5
- Justification:
- Default value for workers according to ECHA REACH Guidance
- AF for the quality of the whole database:
- 1
- Justification:
- The DNEL is based on a high-quality study
- AF for remaining uncertainties:
- 1
- Justification:
- No remaining uncertainties
Acute/short term exposure
- Hazard assessment conclusion:
- no hazard identified
- Most sensitive endpoint:
- acute toxicity
- Route of original study:
- Dermal
DNEL related information
Local effects
Long term exposure
- Hazard assessment conclusion:
- no hazard identified
- Most sensitive endpoint:
- skin irritation/corrosion
Acute/short term exposure
- Hazard assessment conclusion:
- no hazard identified
- Most sensitive endpoint:
- skin irritation/corrosion
Workers - Hazard for the eyes
Local effects
- Hazard assessment conclusion:
- no hazard identified
Additional information - workers
No DNELs have been derived for the short-term dermal and inhalation exposure of the test substance for workers, as it is assumed that the assessment of hazard is sufficiently covered by deriving the respective DNELs for long-term exposure. No quantitative dose-response data are available for local short-term effects on skin and respiratory tract of the test substance.
The long-term worker DNEL for dermal systemic effects is based on a combined chronic toxicity/carcinogenicity study performed according to OECD 453 (M-281767-01-1, 2006). In this study, the test substance was administered to groups of 60 male and 60 female rats by continuous dietary treatment at 1000, 4000 and 8000 ppm, corresponding to 39, 159 and 321 mg/kg bw/day in males and 56, 220 and 447 mg/kg bw/day in females, respectively, over a 24-month period. Additionally, groups of 10 male and 10 female rats were treated at 200, 1000, 4000 and 8000 ppm cyprosulfamide, corresponding to 9, 45, 181 and 364 mg/kg bw/day in males and 13, 62, 249 and 491 mg/kg bw/day in females, over a 12-month period to investigate chronic toxicity only. The mortality rate was higher in females at 8000 ppm after 24 months of treatment and was largely due to secondary treatment-related nephropathy following administration. Mean cumulative body weight gain was reduced during the first week of treatment by 7 and 12% in males and females treated at 8000 ppm, respectively, compared to the controls. Urinalysis revealed the presence of sulfonamide-like crystals throughout the study in both sexes, the effect being more pronounced in females than in males. At the 12-month interim sacrifice, treatment-related non-neoplastic findings were seen microscopically in the kidney and the urinary bladder. At the 24-month sacrifice, treatment-related effects were found in the urinary tract, i.e. kidney, urinary bladder, and ureters. These changes were due to treatment-induced nephropathy, characterized in the kidney by a combination of hyperplastic and inflammatory changes associated with the presence of stones. Urothelial hyperplasia was noted in the urinary bladder in both sexes at the 12-month interim sacrifice, whereas intraluminal stones and multifocal/diffuse urothelial hyperplasia were also observed in the urinary bladder and in a number of ureters in both sexes at the carcinogenicity phase. A slightly higher incidence of the commonly occurring lesion diffuse bilateral tubular degeneration of the testis and bilateral oligospermia of the epididymis was observed at the carcinogenicity phase. Neoplastic changes comprised of a high dose-related transitional cell carcinoma in the kidney of one male and a transitional cell carcinoma in the urinary bladder of one female. These findings, seen only at 8000 ppm, were considered to be secondary to the combination of hyperplastic and inflammatory changes associated with the presence of stones. Thus, the test substance was considered not to be directly carcinogenic in the rat. The NOAEL over a 24 month period of dietary administration with the test substance was 1000 ppm in both sexes (equivalent to 39 mg/kg bw/day in males and 56 mg/kg bw/day in females).
The oral NOAEL of 39 mg/kg bw/day was chosen as starting point for deriving the dermal DNEL as there is no dermal repeated dose toxicity study. To convert the oral NOAEL [mg/kg bw/day] into a dermal NAEL [mg/kg bw/day], the differences in absorption between routes as well as differences in dermal absorption between rats and humans have to be accounted for (Guidance on information requirements and chemical safety assessment. Chapter R.8: Characterisation of dose [concentration]-response for human health, European Chemicals Agency, Version 2.1, November 2012).
For the test substance, an in vitro dermal penetration study using human skin is available (M-279026-01-2, 2006). The study was performed by the use of the test substance in an agrochemical formulation (SC450) at two concentrations: the neat product (nominal value = 225 mg/mL) and a representative spray dilution (nominal value =0.27 mg/mL) were tested. For the neat product, the mean percentage of the test substance considered to be potentially absorbable over a period of 24 h was 0.85%. For the spray dilution, the mean percentage of the test substance potentially absorbable over a period of 24 h was1.5%. As the workers will only be exposed to the formulation and not to the active substance, the % absorbed through the human skin assessed by the study is taken into account in the DNEL derivation.
The long-term worker DNEL for inhalation systemic effects is again based on the combined chronic toxicity/carcinogenicity performed according to OECD 453 (M-281767-01-1, 2006). This study was chosen as the starting point for deriving the inhalation DNEL as there is no inhalation repeated dose study. According to the “Guidance on information requirements and chemical safety assessment. Chapter R.8: Characterisation of dose [concentration]-response for human health” (European Chemicals Agency, Version 2.1, November 2012), the oral NOAEL should be converted into an inhalatory NAEC: the oral dose for the rat is converted to the corresponding air concentration using a standard breathing volume for the rat (0.38 m³/kg for 8 h exposure). Additionally, it should be taken into account that during 8 h light activity at work the respiratory rate becomes higher (10 m³/person) than standard (6.7 m³/person). Considering these differences, the corrected starting point is a NAEC of 68.8 mg/m³. No allometric scaling factor for the rat was included since differences have already been considered for correcting the starting point. The absorption via the inhalation route is considered to be in the same order as via the oral route. No treatment-related effects were observed for acute toxicity via the oral or inhalation exposure route using the limit test.
In general, assessment factors (AF) recommended by ECHA (Guidance on information requirements and chemical safety assessment. Chapter R.8: Characterisation of dose [concentration]-response for human health. European Chemicals Agency, Version 2.1, November 2012) were used when applicable to derive the DNELs. Several AFs for which there is additional information were refined. The difference in metabolic rate between humans and the test species has been taken into account, where relevant. The AF for remaining interspecies differences has been set at 2.5, as the test concentrations (ppm in diet) have been converted into a dose. However, this was only appropriate for the oral and dermal DNEL calculation. The toxicokinetic data indicate that the test substance will not be metabolised (see toxicokinetics). An AF for exposure duration is not applied.
General Population - Hazard via inhalation route
Systemic effects
Long term exposure
- Hazard assessment conclusion:
- DNEL (Derived No Effect Level)
- Value:
- 3.4 mg/m³
- Most sensitive endpoint:
- repeated dose toxicity
- Route of original study:
- Oral
DNEL related information
- DNEL derivation method:
- ECHA REACH Guidance
- Overall assessment factor (AF):
- 10
- Dose descriptor starting point:
- NOAEL
- Value:
- 39 mg/kg bw/day
- Modified dose descriptor starting point:
- NOAEC
- Value:
- 33.9 mg/m³
- Explanation for the modification of the dose descriptor starting point:
The calculation of the DNEL is based on an oral NOAEL observed in an oral combined repeated dose toxicity / carcinogenicity study (OECD 453; 2006).
To correct the interspecies difference between rat and human the NOAEL has to be corrected as follows:
Corrected starting point for the inhalative route for general population:
= NOAEL(oral) * (1/1.15 m³/kg bw/day) * (ABSoral-rat/ABSinh-human)
As described in the ECHA Guidance R.8 (2012), it is assumed that inhalation absorption is 100%. In the toxicokinetic studies with the test substance it was shown that the oral absorption is close to 100%. (ABSoral-rat = oral absorption in rats, ABSinh-human = inhalation absorption rate in humans).
= 39 mg/kg bw/day * (1/1.15 m³/kg bw/day) * (1/1) = 33.9 mg/m³
Thus, the corrected starting point for workers was 33.9 mg/m³ for inhalation.
- AF for dose response relationship:
- 1
- Justification:
- The dose descriptor starting point is based on a NOAEL
- AF for differences in duration of exposure:
- 1
- Justification:
- The DNEL is based on a chronic study
- AF for interspecies differences (allometric scaling):
- 1
- Justification:
- Allometric scaling not used for inhalation route
- AF for other interspecies differences:
- 1
- Justification:
- The toxicokinetic data indicate that the test substance will not be metabolised
- AF for intraspecies differences:
- 10
- Justification:
- Default value for the general population according to ECHA REACH Guidance
- AF for the quality of the whole database:
- 1
- Justification:
- The DNEL is based on a high-quallity study
- AF for remaining uncertainties:
- 1
- Justification:
- No remaining uncertainties
Acute/short term exposure
- Hazard assessment conclusion:
- no hazard identified
- Most sensitive endpoint:
- acute toxicity
- Route of original study:
- By inhalation
DNEL related information
Local effects
Long term exposure
- Hazard assessment conclusion:
- no hazard identified
Acute/short term exposure
- Hazard assessment conclusion:
- no hazard identified
- Most sensitive endpoint:
- acute toxicity
DNEL related information
General Population - Hazard via dermal route
Systemic effects
Long term exposure
- Hazard assessment conclusion:
- DNEL (Derived No Effect Level)
- Value:
- 26 mg/kg bw/day
- Most sensitive endpoint:
- repeated dose toxicity
- Route of original study:
- Oral
DNEL related information
- DNEL derivation method:
- ECHA REACH Guidance
- Overall assessment factor (AF):
- 100
- Dose descriptor starting point:
- NOAEL
- Value:
- 39 mg/kg bw/day
- Modified dose descriptor starting point:
- NOAEL
- Value:
- 2 600 mg/kg bw/day
- Explanation for the modification of the dose descriptor starting point:
The calculation of the dermal DNEL is based on the oral NOAEL of 39 mg/kg bw/day observed in an oral combined repeated dose toxicity / carcinogenicity study (OECD 453; 2006). The NOAEL is corrected to account for dermal penetration rates through human skin. For the test substance, an in vitro dermal penetration study using human skin is available (M-279026-01-2, 2006). The study was performed by the use of the test substance in an agrochemical formulation (SC450) at two concentrations: the neat product (nominal value = 225 mg/mL) and a representative spray dilution (nominal value = 0.27 mg/mL) were tested. For the neat product, the mean percentage of the test substance considered to be potentially absorbable over a period of 24 h was 0.85%. For the spray dilution, the mean percentage of the test substance potentially absorbable over a period of 24 h was 1.5%. As the workers will only be exposed to the formulation and not to the active substance, the % absorbed through the human skin assessed by the study is taken into account in the DNEL derivation. The oral absorption rate is assumed to be 100%, based on almost complete oral absorption seen in the toxicokinetic studies.
Corrected dermal NOAEL = 39 * (100/1.5) = 2600 mg/kg bw/day
- AF for dose response relationship:
- 1
- Justification:
- The dose descriptor starting poiont is based on a NOAEL
- AF for differences in duration of exposure:
- 1
- Justification:
- The DNEL is based on a chronic study
- AF for interspecies differences (allometric scaling):
- 4
- Justification:
- The experimental animal was rat
- AF for other interspecies differences:
- 2.5
- Justification:
- Default value according to ECHA REACH Guidance
- AF for intraspecies differences:
- 10
- Justification:
- Default value for the general population according to ECHA REACH Guidance
- AF for the quality of the whole database:
- 1
- Justification:
- The DNEL is based on a high-quality study
- AF for remaining uncertainties:
- 1
- Justification:
- No remaining uncertainties
Acute/short term exposure
- Hazard assessment conclusion:
- no hazard identified
- Most sensitive endpoint:
- acute toxicity
- Route of original study:
- Dermal
DNEL related information
Local effects
Long term exposure
- Hazard assessment conclusion:
- no hazard identified
- Most sensitive endpoint:
- skin irritation/corrosion
Acute/short term exposure
- Hazard assessment conclusion:
- no hazard identified
- Most sensitive endpoint:
- skin irritation/corrosion
General Population - Hazard via oral route
Systemic effects
Long term exposure
- Hazard assessment conclusion:
- DNEL (Derived No Effect Level)
- Value:
- 0.39 mg/kg bw/day
- Most sensitive endpoint:
- repeated dose toxicity
- Route of original study:
- Oral
DNEL related information
- DNEL derivation method:
- ECHA REACH Guidance
- Overall assessment factor (AF):
- 100
- Dose descriptor starting point:
- NOAEL
- Value:
- 39 mg/kg bw/day
- Explanation for the modification of the dose descriptor starting point:
No modification of the dose descriptor starting point is necessary.
- AF for dose response relationship:
- 1
- Justification:
- The dose descriptor starting poiont is based on a NOAEL
- AF for differences in duration of exposure:
- 1
- Justification:
- The DNEL is based on a chronic study
- AF for interspecies differences (allometric scaling):
- 4
- Justification:
- The experimental animal was rat
- AF for other interspecies differences:
- 2.5
- Justification:
- Default value according to ECHA REACH Guidance
- AF for intraspecies differences:
- 10
- Justification:
- Default value for general population according to ECHA REACH Guidance
- AF for the quality of the whole database:
- 1
- Justification:
- The DNEL is based on a high-quality study
- AF for remaining uncertainties:
- 1
- Justification:
- No remaining uncertainties
Acute/short term exposure
- Hazard assessment conclusion:
- no hazard identified
- Most sensitive endpoint:
- acute toxicity
- Route of original study:
- Oral
DNEL related information
General Population - Hazard for the eyes
Local effects
- Hazard assessment conclusion:
- no hazard identified
Additional information - General Population
The general population is not exposed to the test substance. However, the long-term consumer DNELs for oral, dermal and inhalation systemic effects have been derived. No DNELs have been derived for the short-term dermal, inhalation and oral exposure for the general population, as it is assumed that the assessment of hazard is sufficiently covered by deriving the respective DNELs for long-term exposure. No quantitative dose-response data are available for local short-term effects on skin and respiratory tract of the test substance.
The long-term DNEL for dermal systemic effects is based on a combined chronic toxicity/carcinogenicity study performed according to OECD 453 (M-281767-01-1, 2006). In this study, the test substance was administered to groups of 60 male and 60 female rats by continuous dietary treatment at 1000, 4000 and 8000 ppm, corresponding to 39, 159 and 321 mg/kg bw/day in males and 56, 220 and 447 mg/kg bw/day in females, respectively, over a 24-month period. Additionally, groups of 10 male and 10 female rats were treated at 200, 1000, 4000 and 8000 ppm cyprosulfamide, corresponding to 9, 45, 181 and 364 mg/kg bw/day in males and 13, 62, 249 and 491 mg/kg bw/day in females, over a 12-month period to investigate chronic toxicity only. The mortality rate was higher in females at 8000 ppm after 24 months of treatment and was largely due to secondary treatment-related nephropathy following administration. Mean cumulative body weight gain was reduced during the first week of treatment by 7 and 12% in males and females treated at 8000 ppm, respectively, compared to the controls. Urinalysis revealed the presence of sulfonamide-like crystals throughout the study in both sexes, the effect being more pronounced in females than in males. At the 12-month interim sacrifice, treatment-related non-neoplastic findings were seen microscopically in the kidney and the urinary bladder. At the 24-month sacrifice, treatment-related effects were found in the urinary tract, i.e. kidney, urinary bladder, and ureters. These changes were due to treatment-induced nephropathy, characterized in the kidney by a combination of hyperplastic and inflammatory changes associated with the presence of stones. Urothelial hyperplasia was noted in the urinary bladder in both sexes at the 12-month interim sacrifice, whereas intraluminal stones and multifocal/diffuse urothelial hyperplasia were also observed in the urinary bladder and in a number of ureters in both sexes at the carcinogenicity phase. A slightly higher incidence of the commonly occurring lesion diffuse bilateral tubular degeneration of the testis and bilateral oligospermia of the epididymis was observed at the carcinogenicity phase. Neoplastic changes comprised of a high dose-related transitional cell carcinoma in the kidney of one male and a transitional cell carcinoma in the urinary bladder of one female. These findings, seen only at 8000 ppm, were considered to be secondary to the combination of hyperplastic and inflammatory changes associated with the presence of stones. Thus, the test substance was considered not to be directly carcinogenic in the rat. The NOAEL over a 24 month period of dietary administration with the test substance was 1000 ppm in both sexes (equivalent to 39 mg/kg bw/day in males and 56 mg/kg bw/day in females).
The oral NOAEL of 39 mg/kg bw/day was chosen as starting point for deriving the dermal DNEL as there is no dermal repeated dose toxicity study. To convert the oral NOAEL [mg/kg bw/day] into a dermal NAEL [mg/kg bw/day], the differences in absorption between routes as well as differences in dermal absorption between rats and humans have to be accounted for (Guidance on information requirements and chemical safety assessment. Chapter R.8: Characterisation of dose [concentration]-response for human health, European Chemicals Agency, Version 2.1, November 2012).
For the test substance, an in vitro dermal penetration study using human skin is available (M-279026-01-2, 2006). The study was performed by the use of the test substance in an agrochemical formulation (SC450) at two concentrations: the neat product (nominal value = 225 mg/mL) and a representative spray dilution (nominal value = 0.27 mg/mL) were tested. For the neat product, the mean percentage of the test substance considered to be potentially absorbable over a period of 24 h was 0.85%. For the spray dilution, the mean percentage of the test substance potentially absorbable over a period of 24 h was 1.5%. The % absorbed through the human skin assessed by the study is taken into account in the DNEL derivation.
The long-term DNEL for inhalation systemic effects is again based on the combined chronic toxicity/carcinogenicity study performed according to OECD 453 (M-281767-01-1, 2006). This study was chosen as the starting point for deriving the inhalation DNEL as there is no inhalation repeated dose study According to the “Guidance on information requirements and chemical safety assessment. Chapter R.8: Characterisation of dose [concentration]-response for human health” (European Chemicals Agency, Version 2.1, November 2012), the oral NOAEL should be converted into an inhalatory NAEC: the oral dose for the rat is converted to the corresponding air concentration using a standard breathing volume for the rat (1.15 m³/kg for 24 h exposure). Therefore, the corrected starting point is a NAEC of 33.9 mg/m³. No allometric scaling or additional interspecies factors were included since interspecies differences have already been considered for correcting the starting point. The absorption via the inhalation route is considered to be in the same order as via the oral route. No treatment-related effects were observed for acute toxicity via the oral or inhalation exposure route using the limit test.
The long-term DNEL for oral systemic effects is also based on the combined chronic toxicity/carcinogenicity study performed according to OECD 453 (M-281767-01-1, 2006). Since the study was performed via the oral route, the value can be used directly to derive the oral DNEL.
In general, assessment factors (AF) recommended by ECHA (Guidance on information requirements and chemical safety assessment. Chapter R.8: Characterisation of dose [concentration]-response for human health. European Chemicals Agency, Version 2.1, November 2012) were used when applicable to derive the DNELs. Several AFs for which there is additional information were refined. The difference in metabolic rate between humans and the test species has been taken into account, where relevant. The AF for remaining interspecies differences has been set at 2.5, as the test concentrations (ppm in diet) have been converted into a dose. However, this was only appropriate for the oral and dermal DNEL calculation. The toxicokinetic data indicates that the test substance will not be metabolised (see toxicokinetics). An AF for exposure duration is not applied.
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.
![ECHA](/o/diss-blank-theme/images/factsheets/A-REACH/factsheet/echa_logo.png)